The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in vaccine rates.
Stock.adobe.com
While it may appear that public perception has shifted, a new poll suggests that vaccines are still highly popular and that most people are concerned about dropping vaccine rates.1
The Partnership to Fight Infectious Disease (PFID) announced the results of a bipartisan poll conducted by Public Opinion Strategies and Lake Research Partners. According to the poll, respondents from both major political parties in the US shared similar views on vaccines.
In a press release, Public Opinion Strategies co-founder and partner Neil Newhouse said, “Vaccines remain a critical public health issue with support from voters across the political spectrum. It's important to recognize that despite political differences, Americans recognize a fundamental need to protect themselves, their families, and their communities through vaccines.”
According to the poll, which included registered voters across the US, nearly 70% of respondents showed concern about falling vaccine rates. Nearly three-quarters of respondents said they believed that FDA-approved vaccines should be available and that this should be a priority of the government.
David Mermin, partner at Lake Research Partners, explained, “Despite political divides on some health issues, it is heartening to see a clear consensus around the importance of vaccines in protecting American families. Ensuring access to accurate information and maintaining trust in healthcare providers will be key to sustaining this support.”
The Partnership to Fight Infectious Disease’s policy director Candace DeMatteis also said, “This poll underscores a fundamental truth: protecting our health through vaccination is not a partisan issue. Notably, vaccines like the ones for polio, measles, and many other serious pathogens are widely regarded as vital for public health. Americans understand the benefits of vaccines in safeguarding our children and communities, and we must continue to prioritize access to vaccines and to credible scientific information to inform decisions.”
The PFID conducted a similar poll last April, this time with Lake Research Partners working with The Tarrance Group.2 That poll found similar results, although it did note a growing concern surrounding a lack of trust in the healthcare industry and important sources of information.
Former governor Howard Dean was quoted in a press release at the time saying, “Maintaining trust in our public health infrastructure is essential, regardless of party affiliation. Over the past several years we have seen increased politicization of vaccines, which has only exacerbated anxiety and uncertainty. The role of political leaders in public health is to help maintain trust, not tear it down.”
Dr Angela Branche, associate professor of medicine at the University of Rochester and a member of PFID public policy and advocacy committee, also said, “While it is reassuring that so many respondents trust the science to get their kids and themselves vaccinated, it’s clear – and these findings show – that there is still more work to be done to remind everyone that vaccines protect families and their communities. As the health care industry works to develop new vaccines to address a number of diseases, we must recommit ourselves to educating patients and medical professionals on the benefits of routine vaccination.”
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.